Transfusion, Volume 66, Issue 4, Page 677-688, April 2026.Abstract Background Heparin combined with sodium citrate has been used in leukocytapheresis for pediatric patients. Since 2022, we have performed leukocytapheresis using a highly concentrated sodium citrate solution (HSC, 5.32%) instead of acid citrate dextrose solution A (ACD‐A).
Keiko Fujii +8 more
wiley +1 more source
Non-signaling protein therapeutics: a mechanism-based regulatory framework to modernize biosimilar development and global harmonization. [PDF]
Front Med (Lausanne)Niazi SK.
europepmc +1 more source
Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab. [PDF]
BMJ Neurol OpenHøgestøl EA +12 more
europepmc +1 more source
The economic pressures for biosimilar drug use in cancer medicine [PDF]
, 2012 Paul Cornes
core +1 more source
Navigating the Transition: A Scoping Review of System-Level Factors in Biosimilar Integration for Immune-Mediated Inflammatory Diseases. [PDF]
BioDrugsKumar S, Dalbeth N, Gasteiger C.
europepmc +1 more source
Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics <i>vs</i> biosimilars. [PDF]
World J GastroenterolMoura CS +10 more
europepmc +1 more source
Nomenclature and Traceability Debate for Biosimilars: Small-Molecule Surrogates Lend Support for Distinguishable Nonproprietary Names [PDF]
, 2015 core +1 more source
Net Present Value Impact of FDA's Phase 3 Waivers on Monoclonal Antibody Biosimilar Development. [PDF]
BiologicsRanbhor R, Kulkarni P.
europepmc +1 more source
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab [PDF]
, 2016 core +1 more source
Past, present and future of nivolumab: new horizons in immuno-oncology. [PDF]
Front OncolMadar IH, Kammarambath SR.
europepmc +1 more source